Revista Brasileira de Hematologia e Hemoterapia Revista Brasileira de Hematologia e Hemoterapia
Rev Bras Hematol Hemoter 2017;39:216-22 DOI: 10.1016/j.bjhh.2017.03.008
Original article
Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
Talita Máira Bueno da Silveira da Rocha, , Sergio Costa Fortier, Thais Rodrigues da Cunha Fischer, Guilherme Fleury Perini, Rafael Dezen Gaiolla, Laura Fogliatto, Marcia Torresan Delamain, Andressa Fragoso da Costa, Nelson Siqueira de Castro, Wolney Gois Barretos, Cármino Antonio de Souza, Valéria Buccheri, Carlos Sérgio Chiattone
Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil
Recebido 02 Setembro 2016, Aceitaram 23 Março 2017
Rev Bras Hematol Hemoter 2017;39:193-6

Despite all the scientific progress that has been made on understanding the disease, prognosis for patients with relapsed and refractory Hodgkin's lymphoma remains poor and the treatment is palliative in the majority of the cases. Thus, the aim of this study was to present the results on the compassionate use of everolimus in a group of patients who were monitored at nine different centers in Brazil.


A 10-mg oral dose of everolimus was given to each patient daily. Response time was evaluated from the beginning of medication use until loss of response, toxicity or medical decision to cease treatment.


Thirty-three patients were evaluated. The median age at the beginning of medication administration was 29 years. Patients had received a median of five prior therapies. Overall response rate was 45.4%, with 13 patients achieving partial response, two achieved clinical response, 14 remained with stable disease, two had disease progression, and two were not evaluated. Patients received a median of 14 cycles. Progression-free survival was nine months, and overall survival was estimated to be 36 months. Three patients used the medication for more than four years. The most frequently reported adverse events were thrombocytopenia and hypercholesterolemia. Three patients had pulmonary toxicity. Grade III and IV adverse events occurred in 39% of the patients.


Everolimus was found to provide a response in a group of patients with refractory or relapsed Hodgkin's lymphoma who had adequate tolerability to the drug.

Everolimus, Hodgkin's lymphoma, Refractory
Rev Bras Hematol Hemoter 2017;39:216-22 DOI: 10.1016/j.bjhh.2017.03.008